Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Bayern's Musiala diagnosed with neurological disorder after two on-field collapses

Bayern's Musiala diagnosed with neurological disorder after two on-field collapses

Bayern Munich's midfielder Jamal Musiala has been diagnosed with a neurological disorder following two on-field collapses in recent matches. The 23-year-old German international experienced his first collapse six minutes into Bayern's 4-2 friendly win against Heidenheim, requiring medical attention before being escorted from the pitch.

A second incident occurred during Bayern's 3-1 friendly victory over RB Leipzig on Saturday. In an Instagram post, Musiala revealed he has been diagnosed with temporary, brief, but easily treatable episodes caused by a neurological dysfunction. While acknowledging the fear these episodes might initially provoke, Musiala emphasized they are a part of his everyday life and he is receiving top medical care.

Doctors have ruled out any further health risks, and Musiala expressed optimism about his recovery. The versatile midfielder, who has made 231 appearances for Bayern, missed six months last season due to a fractured ankle in the Club Cup but returned to play for Germany at the 2026 World Cup.

Written by urgent.news from Business Recorder's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Read the original at channelnewsasia.com →

More in Health & Medicine

Hadassah performs first-ever alpha radiation treatment for recurring brain tumors

The technology, which emits highly bioefficient alpha particles that deliver concentrated radiation, was developed in collaboration with the Sharett Institute of Oncology and ALPHA Tau.

  • Hadassah Medical Center performs first-ever alpha radiation treatment for brain tumors.
  • 77-year-old patient with glioblastoma recurrence becomes Israel's inaugural recipient.
  • Alpha DaRT technology developed in collaboration with Sharett Institute of Oncology and ALPHA Tau.

More from Wednesday 19 August →